Adenoviral vectors for liver-directed gene therapy

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 565-572

  Connelly, Sheila ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenoviral vector; Gene therapy; Gutless vectors; Helper virus; Hepatocyte; Transgene

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HELPER VIRUS; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; LIVER CELL; LIVER DISEASE; LIVER TOXICITY; NONHUMAN; REVIEW; TRANSGENE;

EID: 0032736676     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Shenk T: Adenoviridae: the viruses and their replication. In: Fields Virology, Fields BN, Knipe DM, Howley PM (Eds). Lippincott-Raven (1996):2111-2148.
2. Berkner KL: Development of adenovirus vectors for the expression of heterologous genes. Biotechniques (1988) 6:616-629.
3. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M: Sustained expression of therapeutic levels of human factor VIII in mice. Blood (1996) 87:4671-4677.
4. Connelly S, Andrews J, Gallo AM, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M: Sustained phenotypic correction of murine hemophilia A by In vivo gene therapy. Blood (1998) 91:3273-3281.
5. Wang Q, Greenburg G, Bunch D, Parson D, Finer MH: Persistent transgene expression in mouse liver following In vivo gene transfer with a deltaE1/deltaE4 adenovirus vector. Gene Ther (1997) 4:393-400.
6. Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notely C, Hough C, Lillicrap D, Kaleko M, Connelly S: In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther (1999) 10:1791-1802.
7. Stratford-Perricaudet LD, Levrero M, Chasse J, Perricaudet M, Briand P: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther (1990) 1:241-256.
8. Morsey MA, Alford EL, Bett A, Graham FL, Caskey CT: Efficient adenoviral-mediated ornithine transcarbamylasc expression in deficient mouse and human hepatocytes. J Clin Invest (1993) 92:1580-1586.
9. Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM: Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem (1996) 271:3639-3646.
10. Ye X, Robinson MB, Pabin C, Quinn T, Jawad A, Wilson JM, Batshaw ML: Adenovirus-mediatedin vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr Res (1997) 41:527-534.
11. Kiwaki K, Matsuda I: Gene therapy for ornithine transcarbamylase deficiency. Acta Paediatr Jpn (1996) 38:189-192.
12. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest (1993) 92:883-893.
13. Stevenson SC, Marshell-Neff J, Teng B, Lee CB, Roy S, McClelland A: Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol (1995) 15:479-484.
14. Kozarsky KF, Jooss K, Donahee M, Strauss JF, Wilson JM: Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nature Genet (1996) 13:54-62.
15. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM: In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem (1994) 269:13695-13702.
16. Li J, Fang B, Eisensmith RC, Li XH, Nasokin I, Lin-Lee YC, Mins MP, Hughes A, Montgomery CD, Roberts JD: In vivo gene therapy for hyperlipidemia: phenotypic correction In Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest (1995) 95:768-773.
17. Fang B, Eisensmith RC, Li XH, Finegold MJ, Sheldlovsky A, Dove W, Woo SL: Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther (1994) 1:247-254.
18. Kay MA, Graham F, Leland F, Woo SL: Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology (1995) 21:815-819.
19. Takahashi M, Ilan Y, Chowdhury NR, Guida J, Horowitz M, Chowdhury JR: Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a reccmbinant adenovirus during the neonatal period. J Biol Chem (1996) 271:26536-26542.
20. Kubo S, Kiwaki K, Awata H, Katoh H, Kanegae Y, Saito I, Yamamoto T, Miyazaki J, Matsuda I, Endo F: In vivo correction with recombinant adenovirus of 4-hydroxyphenylpyruvic acid dioxygenase deficiencies in strain III mice. Hum Gene Ther (1997) 8:65-71.
21. Overturf K, Al-Dhalimy M, Ou CN, Finegold M, Tanguay R, Lieber A, Kay M, Grompe M: Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type 1. Hum Gene Ther (1997) 8:513-521.
22. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD: Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood (1996) 88:3846-3853.
23. Connelly S, Kaleko M: Haemophilia A gene therapy. Haemophilia (1998) 4:380-388.
24. Kay MA, Landen CN, Rothenburg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SL: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA (1994) 91:2353-2357.
25. Kay MA: Hepatic gene therapy for haemophilia B. Haemophilia (1998) 4:389-392.
26. Anderson WF: Human gene therapy. Nature (1998) 392:25-30.
27. Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M: Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet (1993) 5:397-402.
28. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther (1995) 6:185-193.
29. Brann T, Kayda DB, Lyons R, Shirley P, Roy S, Kaleko M, Smith TAG: Adenoviral vector-mediated expression of physiological levels of human factor VIII in non-human primates. Hum Gene Ther (1999) in press.
30. Connelly S, Gardner JM, McClelland A, Kaleko M: High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther (1996) 7:183-195.
31. Connelly S, Andrews JL, Gallo Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M: Evaluation of an adenoviral vector encoding full-length factor VIII in hemophiliac mice. Thromb Haemost (1999) 81:234-239.
32. Andrews JL, Weaver L, Kaleko M, Connelly S: Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. Haemophilia (1999) 5:160-168.
33. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SLC: Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapyin vivo. Gene Ther (1996) 3:980-987.
34. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SLC, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA (1996) 93:11302-11306.
35. Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R, Glaspy JA, McBride WH, Economou JS: In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther (1997) 8:2173-2182.
36. Kaneko S, Halenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res (1995) 55:5283-5287.
37. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SL: Combination gene therapy for liver metastasis of colon carcinomain vivo. Proc Natl Acad Sci USA (1995) 92:2577-2581.
38. Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P: Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther (1998) 5:1105-1113.
39. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, Lu H: Angiostatin gene transfer: Inhibition of tumor growthin vivo by blockage of endothelial cell proliferation associated with a mitosis arrest Proc Natl Acad Sci USA (1998) 95:6367-6372.
40. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA: Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol (1996) 70:8782-8791.
41. Desai U, Slosberg E, Caplan S, Bottcher B, Kaleko M, Connelly S: Treatment of type 2 diabetes through adenovirus mediated overexpression of glucokinase in a diet-induced diabetic murine model. Am Soc Gene Ther (1999) 2:Abs 47.
42. Yang Y, Nunes FA, Berensci K, Furth EE, Gönczöl E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA (1994) 91:4407-4411.
43. Yang Y, Ertl HCJ, Wilson JM: MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 1:433-442.
44. Tripathy SK, Black HB, Goldwasser E, Leiden JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med (1996) 5:545-550.
45. Hu H, Serra D, Amalfitano A: Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther (1999) 10:355-364.
46. Morral N, O'Neal W, Zhou H, Langsten C, Beaudet A: Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther (1997) 8:1275-1286.
47. Barr D, Tubb J, Ferguson D, Sana A, Lieber A, Wilson C, Perkins J, Kay MA: Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther (1995) 2:151-155.
48. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC: Gene therapy for hemophilia B: Host Immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther (1995) 6:1039-1044.
49. Vilquin J, Guérette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay JP: FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther (1995) 6:1391-1401.
50. Lochmüller H, Petrof BJ, Allen C, Presscott S, Massie B, Karpati G: Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. Biochem Biophys Res Commun (1995) 213:569-574.
51. Lochmüller H, Petrof BJ, Pari G, Larochelle N, Dodelet V, Wang Q, Allen C, Presscott S, Massie B, Nalbantoglu J, Karpati G: Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther (1996) 3:706-716.
52. Jooss K, Yang Y, Wilson JM: Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther (1996) 7:1555-1566.
53. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA (1995) 92:1401-1405.
54. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration. Nature Genet (1995) 11:191-197.
55. Guéreete B, Vilquin JT, Gingras M, Gravel C, Wood KJ, Tremblay JP: Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4lg. Hum Gene Ther (1996) 7:1455-1463.
56. Yang Y, Greenough K, Wilson JM: Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther (1996) 3:412-420.
57. Roy S, Shirley PS, McClelland A, Kaleko M: Circumvention of immunity to the adenovirus major coat protein hexon. J Virol (1998) 72:6875-6879.
58. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E: Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther (1996) 3:154-162.
59. Mastrangeli IA, Harvey BG, Yao J, Wolff G, Kovesdi I, Crystal RG, Falck-Pedersen E: 'Sero-switch' adenovirus-mediated In vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther (1996) 7:79-87.
60. Smith TAG, White BD, Gardner JM, Kaleko M, McClelland A: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther (1996) 3:496-502.
61. Yang Y, Trinchieri G, Wilson JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med (1995) 1:890-893.
62. Yang Y, Su Q, Grewal IS, Schliz R, Flavell RA, Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol (1996) 70:6370-6377.
63. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbough D, Arrufo A, Ochs HD, Wilson CB: Transient immunomodulation with anti-CD40 ligand antibody and CTLA4lg enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA (1997) 94:4686-4691.
64. Walter J, You Q, Hagstrom JN, Sands M, High KA: Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci USA (1996) 93:3056-3061.
65. Ilan Y, Attavar P, Takahashi M, Davidson A, Horowitz MS, Guida J, Chowdhury NR, Chowdhury JR: Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest (1996) 98:2640-2647.
66. Ilan Y, Prakash R, Davidson A, Jona, Droguett G, Horowitz MS, Chowdhury NR, Chowdhury JR: Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest (1997) 99:1098-1106.
67. Morsy MA, Caskey CT: Expanded-capacity adenoviral vectors-the helper-dependent vectors. Mol Med Today (1999) 5:18-24.
68. Mittereder N, Yei S, Bachurski C, Cuppoletti J, Whitsett JA, Tolstoshev P, Trapnell BC: Evaluation of the efficacy and safety of in vitro adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther (1994) 5:717-729.
69. Yang Y, Li Q, Ertl HC, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 69:2004-2015.
70. Yang Y, Su Q, Wilson JM: Role of viral antigens In destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 70:7209-7212.
71. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA (1994) 91:6196-6200.
72. Yang Y, Nunes FA, Berencsi K, Gönczöl E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet (1994) 7:362-369.
73. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC: Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther (1996) 3:217-222.
74. Gorziglia Ml, Kadan MJ, Yei S, Lim J, Lee GM. Luthra R, Trapnell BC: Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol (1996) 6:4173-4178.
75. Brough DE, Hsu C, Kulesa VA, Lee GM, Cantolupo LJ, Lizonova A, Kovesdi I: Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors In vivo. J Virol (1997) 71:9206-9213.
76. Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Aubailiy N, Orsini C, Guillaume JM, Opolon P, Delaere P, Perricaudet M, Yeh P: Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol (1997) 71:4626-4637.
77. Gao GP, Yang Y, Wilson JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 70:8934-8943.
78. Lusky M, Christ M, Rittner K, Dieterte A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M: In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol (1998) 72:2022-2032.
79. Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan MJ, Wu V, Pechan PA, Kaleko M: Generation of an adenovirus vector lacking E1, E2a, E3 and all of E4 except open reading frame 3. J Virol (1999) 73:6048-6055.
80. Parks RJ, Graham FL: A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol (1997) 71:3293-3298.
81. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT: An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA (1998) 95:7866-7871.
82. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 71:1842-1849.
83. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC. Langsten C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet (1998) 18:180-183.
84. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA (1996) 93:5731-5736.
85. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA (1996) 93:13565-13570.
86. Kilby NJ, Snaith MR, Murray J: Site-specific recombinases; tools for genome engineering. Trends Genet (1993) 9:413-421.
87. Webster KA: Molecular switches for regulating therapeutic genes. Gene Ther (1999) 6:951-953.
88. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW: Adenovirus-mediated regulable target gene expressionin vivo. Proc Natl Acad Sci USA (1999) 96:355-360.
89. Reynolds PN, Feng M, Curiel DT: Chimeric viral vectors the best of both worlds? Mol Med Today (1999) 5:25-31.
90. Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F, Ciliberto G, Graham FL, Cortese R, La Monica N, Colloca S: Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA (1999) 96:2615-2620.
91. Feng M, Jackson WH Jr, Goldman CK, Rancourt C, Wang M, Dusing SK, Siegal G, Curiel DT: Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnol (1997) 15:866-870.
92. Caplen NJ, Higginbotham J, Scheel JR, Vahanian N, Yoshida Y, Hamada H, Blaese RM, Ramsey WJ: Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther (1999) 6:454-459.